title: [Cytomegalovirus infection after haploidentical stem cell transplantation may reduce relapse risk in leukemia].
abstract: OBJECTIVE
  To analyze the relationship between cytomegalovirus (CMV) reactivation and leukemia relapse after haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
  
  
  METHODS
  A total of 61 patients diagnosed as hematological malignancies undergoing haplo-HSCT were analyzed retrospectively in our center.
  
  
  RESULTS
  In the cohort, 36 patients had CMV reactivation after haplo-HSCT. The 100-day cumulative incidence of CMV reactivation was 59%. Compared with that in patients without CMV reactivation after transplantation, the incidence of leukemia relapse was lower in patients with CMV reactivation (16.9% vs 40.0%, P=0.034). The correlation of CMV reactivation and decreased relapse rate was only found in patients with acute myeloid leukemia (P=0.019). In multivariate analysis, relapsed disease status before transplant was a significant negative predictor of overall survival (OS) and relapse after transplant (RR was 2.866 and 3.331 respectively). CMV reactivation after transplant had a protective effect on disease relapse (RR=0.300, P=0.047).
  
  
  CONCLUSIONS
  The rate of CMV reactivation after haplo-HSCT is high. CMV reactivation may reduce risk of relapse in patients diagnosed as acute myeloid leukemia undergoing haplo-HSCT. However, CMV reactivation is one of the important predictors of non-relapse death after transplant, active anti-viral treatment is still needed.
authors.affiliation: Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, China.
authors.forename: Xia
authors.initials: X
authors.lastname: Lin
authors.forename: Ying
authors.initials: Y
authors.lastname: Ou
authors.forename: Hui
authors.initials: H
authors.lastname: Long
authors.forename: Yuxian
authors.initials: Y
authors.lastname: Huang
authors.forename: Chaoyang
authors.initials: C
authors.lastname: Song
authors.forename: Zhigang
authors.initials: Z
authors.lastname: Lu
authors.forename: Kunyuan
authors.initials: K
authors.lastname: Guo
authors.forename: Bingyi
authors.initials: B
authors.lastname: Wu
authors.forename: Jianhui
authors.initials: J
authors.lastname: Xu
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D003587:Cytomegalovirus; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000473:pathology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015994:Incidence; D015470:Leukemia, Myeloid, Acute / Q000628:therapy* / Q000821:virology; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D014184:Transplantation, Homologous; D014775:Virus Activation
chemical_list: D000998:Antiviral Agents